Chemours Co(CC)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Chemours Co (CC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CC at 43.4/100 on a 32-signal composite quality model, placing it at rank #1,968 of 2,962 stocks — the bottom half of the AI-ranked universe. CC scores in the top quartile across revenue scale (79.9). Areas of concern include balance sheet strength (23.5) and revenue growth (24.7), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Chemours Co reports quarterly revenue of $1.6B, net income of $-274.0M, an operating margin of -0.1%. Top institutional holders of CC by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CC trades on the NYSE exchange and files with the SEC under CIK 1627223. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Chemours Co directly from SEC EDGAR.
AI Quality Score
43.4/100
AI Rank
#1,968
Revenue
$1.6B
Net Income
$-274.0M
Free Cash Flow
$114.0M
Operating Margin
-0.1%
CC key financials by period
Chemours Co reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$5.8B
$-386.0M
-4.8%
FY 2024
10-K
$5.8B
$69.0M
1.8%
FY 2023
10-K
$6.1B
$-253.0M
-5.2%
FY 2022
10-K
$6.8B
$578.0M
10.8%
FY 2021
10-K
$6.3B
$608.0M
10.7%
FY 2020
10-K
$5.0B
$219.0M
3.6%
Institutions holding CC
Institutional investors reporting a position in Chemours Co on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Chemours reported Q2 revenue of $1,591M, down 1% YoY, with net loss of $274M driven by $273M tax provision from valuation allowances and $552M accrued PFAS litigation liabilities.
Biggest Revenue Drivers
Titanium Technologies$661M+1% YoY
Titanium dioxide sales flat at $639M; minerals & other at $22M.
Lower production costs offset by unfavorable product mix.
Selling, general, and administrative expense$469M+11% YoY
Increased litigation and legal defense costs, including indemnification agreement advances.
Interest expense, net$68M+1% YoY
Higher debt levels and interest rates offset by debt repayments.
Watch Items from the Filing
PFAS litigation reserves surged to $552M (Other PFAS matters) from $344M, with New Jersey settlement accrual of $269M on net present value basis; reasonably possible additional exposure estimated at $700M+ above accrued amounts.
Tax provision of $273M on $1M loss before taxes reflects full valuation allowance recognized on U.S. federal/state deferred tax assets including ~$208M prior-year adjustments, indicating significant tax uncertainty.
Environmental remediation liabilities increased to $795M from $618M; Fayetteville off-site drinking water program alone at $139M with potential RFS ranges of $177M–$1,048M at primary responsible party sites.
Long-term debt net of $3,838M; Euro term loan reduced by €230M ($25M equivalent) in Q2; refinanced $495M May 2027 notes via $700M March 2034 issuance at 7.875%, extending maturity profile.
Audit Committee internal review findings (Q1 2024) identified Code of Ethics violations by former CEO, CFO, Controller; SEC subpoenas outstanding; securities class actions and derivative suits pending; indemnification advancement requests ongoing.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
